Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
Yoshimi Enose-Akahata, Bridgette Jeanne Billioux, Shila Azodi, Jennifer Dwyer, Ashley Vellucci, Nyater Ngouth, Satoshi Nozuma, Raya Massoud, Irene Cortese, Joan Ohayon, Steven Jacobson, Yoshimi Enose-Akahata, Bridgette Jeanne Billioux, Shila Azodi, Jennifer Dwyer, Ashley Vellucci, Nyater Ngouth, Satoshi Nozuma, Raya Massoud, Irene Cortese, Joan Ohayon, Steven Jacobson
Abstract
Objective: Human T-cell lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP. Recently, it was shown that raltegravir could inhibit cell-free and cell-to-cell transmission of HTLV-1 in vitro. Given the substantial clinical experience in human immunodeficiency virus infection and its excellent safety profile, this agent may be an attractive therapeutic option for HAM/TSP patients.
Methods: Sixteen subjects with HAM/TSP received raltegravir 400 mg orally twice daily in an initial 6-month treatment phase, followed by a 9-month post-treatment phase. HTLV-1 PVLs were assessed using droplet digital PCR from the PBMCs every 3 months, and from the CSF at baseline, month 6, and month 15. We also evaluated the ability of raltegravir to regulate abnormal immune responses in HAM/TSP patients.
Results: While a downward trend was observed in PBMC and/or CSF PVLs of some patients, raltegravir overall did not have any impact on the PVL in this HAM/TSP patient cohort. Clinically, all patients' neurological scores and objective measurements remained relatively stable, with some expected variability. Immunologic studies showed alterations in the immune profiles of a subset of patients including decreased CD4+ CD25+ T cells and spontaneous lymphoproliferation.
Interpretation: Raltegravir was generally well tolerated in this HAM/TSP patient cohort. A subset of patients exhibited a mild decrease in PVL as well as variations in their immune profiles after taking raltegravir. These findings suggest that raltegravir may be a therapeutic option in select HAM/TSP patients.
Clinical trial registration number: NCT01867320.
Conflict of interest statement
The authors have declared that no conflict of interest exists.
© 2021 Published 2021. This article is a U.S. Government work and is in the public domain in the USA. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Figures
References
- Gessain A, Vernant JC, Maurs L, et al. Antibodies to human T‐lymphotropic virus type‐I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452):407‐470.
- Osame M, Usuku K, Izumo S, et al. HTLV‐I associated myelopathy, a new clinical entity. Lancet. 1986;1(8488):1031‐1032.
- Umehara F, Izumo S, Nakagawa M, et al. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV‐I‐associated myelopathy. J Neuropathol Exp Neurol. 1993;52(4):424‐430.
- Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. Increased HTLV‐I proviral load and preferential expansion of HTLV‐I Tax‐specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol. 2001;50(6):807‐812.
- Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV‐I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV‐I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586‐593.
- Yamano Y, Nagai M, Brennan M, et al. Correlation of human T‐cell lymphotropic virus type 1 (HTLV‐1) mRNA with proviral DNA load, virus‐specific CD8(+) T cells, and disease severity in HTLV‐1‐associated myelopathy (HAM/TSP). Blood. 2002;99(1):88‐94.
- Yamano Y, Araya N, Sato T, et al. Abnormally high levels of virus‐infected IFN‐gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus‐associated neuroinflammatory disorder. PLoS One. 2009;4(8):e6517.
- Yamano Y, Takenouchi N, Li H‐C, et al. Virus‐induced dysfunction of CD4+CD25+ T cells in patients with HTLV‐I‐associated neuroimmunological disease. J Clin Invest. 2005;115(5):1361‐1368.
- Enose‐Akahata Y, Azodi S, Smith BR, et al. Immunophenotypic characterization of CSF B cells in virus‐associated neuroinflammatory diseases. PLoS Pathog. 2018;14(4):e1007042.
- Brooks KM, Sherman EM, Egelund EF, et al. Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacotherapy. 2019;39(5):576‐598.
- Seegulam ME, Ratner L. Integrase inhibitors effective against human T‐cell leukemia virus type 1. Antimicrob Agents Chemother. 2011;55:2011‐2017.
- Barski MS, Minnell JJ, Maertens GN. Inhibition of HTLV‐1 infection by HIV‐1 first‐ and second‐generation integrase strand transfer inhibitors. Front Microbiol. 2019;10:1877.
- Trevino A, Parra P, Bar‐Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV‐1 carriers. J Antimicrob Chemother. 2012;67(1):218‐221.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444‐1452.
- Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology. 1984;34(10):1368‐1372.
- Kaufman M, Moyer D, Norton J. The significant change for the Timed 25‐foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6(4):286‐290.
- Schmidt F, Oliveira AL, Araujo A. Development and validation of a neurological disability scale for patients with HTLV‐1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): the IPEC‐1 scale. Neurology. 2012;78(supplement 1):P03258.
- Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three‐arm study of high‐dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308(4):173‐180.
- Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box‐and‐block and nine‐hole peg tests. Arch Phys Med Rehabil. 1988;69(10):850‐854.
- Brunetto GS, Massoud R, Leibovitch EC, et al. Digital droplet PCR (ddPCR) for the precise quantification of human T‐lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. J Neurovirol. 2014;20(4):341‐351.
- Enose‐Akahata Y, Ngouth N, Ohayon J, et al. Effect of teriflunomide on cells from patients with human T‐cell lymphotropic virus type 1‐associated neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e986.
- Oh U, Yamano Y, Mora CA, et al. Interferon‐beta1a therapy in human T‐lymphotropic virus type I‐associated neurologic disease. Ann Neurol. 2005;57(4):526‐534.
- Enose‐Akahata Y, Abrams A, Massoud R, et al. Humoral immune response to HTLV‐1 basic leucine zipper factor (HBZ) in HTLV‐1‐infected individuals. Retrovirology. 2013;10:19.
- Enose‐Akahata Y, Vellucci A, Jacobson S. Role of HTLV‐1 Tax and HBZ in the pathogenesis of HAM/TSP. Front Microbiol. 2017;8:2563.
- Matsuoka M, Jeang KT. Human T‐cell leukaemia virus type 1 (HTLV‐1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270‐280.
- Saito M, Matsuzaki T, Satou Y, et al. In vivo expression of the HBZ gene of HTLV‐1 correlates with proviral load, inflammatory markers and disease severity in HTLV‐1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology. 2009;6:19.
- Enose‐Akahata Y, Jacobson S. Immunovirological markers in HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology. 2019;16(1):35.
- Azimi N, Jacobson S, Leist T, Waldmann TA. Involvement of IL‐15 in the pathogenesis of human T lymphotropic virus type I‐associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL‐2/15R beta receptor. J Immunol. 1999;163(7):4064‐4072.
- Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV‐I‐associated myelopathy. Neurology. 1988;38(8):1302‐1307.
- Bangham CR, Araujo A, Yamano Y, Taylor GP. HTLV‐1‐associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers. 2015;1:15012.
- Matsuzaki T, Nakagawa M, Nagai M, et al. HTLV‐I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol. 2001;7(3):228‐234.
- Demontis MA, Hilburn S, Taylor GP. Human T cell lymphotropic virus type 1 viral load variability and long‐term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1‐related diseases. AIDS Res Hum Retroviruses. 2013;29(2):359‐364.
- Hanon E, Hall S, Taylor GP, et al. Abundant tax protein expression in CD4+ T cells infected with human T‐cell lymphotropic virus type I (HTLV‐I) is prevented by cytotoxic T lymphocytes. Blood. 2000;95(4):1386‐1392.
- Gillet NA, Malani N, Melamed A, et al. The host genomic environment of the provirus determines the abundance of HTLV‐1‐infected T‐cell clones. Blood. 2011;117(11):3113‐3122.
- Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, Bangham CR. Genome‐wide determinants of proviral targeting, clonal abundance and expression in natural HTLV‐1 infection. PLoS Pathog. 2013;9(3):e1003271.
- Gross C, Thoma‐Kress AK. Molecular mechanisms of HTLV‐1 cell‐to‐cell transmission. Viruses. 2016;8(3):74.
- Fox J, Hilburn S, Demontis M‐A, et al. Long terminal repeat circular DNA as markers of active viral replication of human T lymphotropic virus‐1 in vivo. Viruses. 2016;8(3):80.
- Yamano Y, Cohen CJ, Takenouchi N, et al. Increased expression of human T lymphocyte virus type I (HTLV‐I) Tax11‐19 peptide‐human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide‐specific, major histocompatibility complex‐restricted antibodies in patients with HTLV‐I‐associated neurologic disease. J Exp Med. 2004;199(10):1367‐1377.
- Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3(3):219‐227.
- Yamano Y, Sato T. Clinical pathophysiology of human T‐lymphotropic virus‐type 1‐associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.
Source: PubMed